Gilead Sciences (GILD) PT Raised at Cowen as HCV Sales Drive Beat
Get Alerts GILD Hot Sheet
Rating Summary:
24 Buy, 17 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 10 | Down: 11 | New: 6
Join SI Premium – FREE
Cowen analyst Phil Nadeau reiterated an Outperform rating and bumped his price target on Gilead Sciences (NASDAQ: GILD) to $130.00 (from $125.00) as HCV sales drove the top and bottom-line and guidance was ralsed.
Nadeau commented, "Gilead reported solid Q3 financials with HCV revenue ($4.8B vs $4.4BE), product sales ($8.2B vs $7.8BE), and non-GAAP EPS ($3.22 vs $2.83E) all ahead of consensus. While U.S. HCV scrips have been in decline for six months, Gilead thinks trends are stabilizing. We have adjusted our ests to reflect current trends, and our PT has increased from $125 to $130."
For an analyst ratings summary and ratings history on Gilead Sciences click here. For more ratings news on Gilead Sciences click here.
Shares of Gilead Sciences closed at $110.96 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- ASM International NV (ASM:NA) PT Raised to EUR720 at Citi
- Atlas Copco AB (ATCOA:SS) (ATLKY) PT Raised to SEK150 at RBC Capital
- Cidara Therapeutics (CDTX) PT Raised to $25 at Needham
Create E-mail Alert Related Categories
Analyst Comments, Analyst EPS Change, Analyst EPS View, Analyst PT ChangeRelated Entities
Cowen & CoSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!